The recent resurgence in microbial fermentation for biologics production can be attributed to many factors. Advances in biochemistry and a growing understanding of when glycosylation is not needed […] […]
Drug development, regardless of the modality, invariably involves some level of risk. As mRNA therapeutics advance, they too will face such risks, including some […] […]
The outlook for mRNA vaccines and therapeutics continues to be promising, with demand expected to increase as many candidates move into late-stage clinical development and on toward commercialization. With […] […]
Pharmaceutical supply chains are susceptible to sudden changes in demand or disruptions in what is still largely a centralized manufacturing system. This was highlighted during the COVID-19 pandemic, when access to vaccines, medications and test […] […]
BIOVECTRA, a CDMO based in Atlantic Canada has established its presence in the industry – and it is not slowing down any time soon. From its experience providing diagnostic reagents, enzymes and APIs, it has over the past five decades evolved it’s product […] […]
Since the beginning of the COVID-19 pandemic, pharmaceutical organizations have experienced major changes, a prime example of which has been the rising requirement for collaborations on multiple different fronts across the industry […] […]
Biologics have revolutionized drug delivery, offering innovative therapies for a range of diseases, including cancers, autoimmune and other genetic disorders, and infectious diseases. To meet booming demand […] […]
Validating the effectiveness of the cleaning of pharmaceutical manufacturing and process equipment is part of good manufacturing practices (GMPs) (1,2). Regulators expect manufacturers to be able to […] […]
Operational excellence relies heavily on an organization being staffed with the adequate amount of properly trained personnel. The pharmaceutical industry has seen an increase in new modalities […] […]
The COVID-19 pandemic put a spotlight on how the bio/pharmaceutical industry and regulators can work together to bring life-saving therapies to the market fast to safeguard and improve public health. The lessons learned […] […]
With over 50 years of experience, we are a forward-thinking,
North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.